Premium
Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril
Author(s) -
Tarkiainen E. Katriina,
Tornio Aleksi,
Holmberg Mikko T.,
Launiainen Terhi,
Neuvonen Pertti J.,
Backman Janne T.,
Niemi Mikko
Publication year - 2015
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12667
Subject(s) - enalaprilat , enalapril , quinapril , pharmacokinetics , genotype , carboxylesterase , endocrinology , medicine , pharmacology , pharmacodynamics , urine , crossover study , chemistry , ace inhibitor , angiotensin converting enzyme , enzyme , biochemistry , placebo , alternative medicine , pathology , gene , blood pressure
Aim The aim of the present study was to investigate the effects of the carboxylesterase 1 (CES1) c.428G > A (p.G143E, rs71647871) single nucleotide variation (SNV) on the pharmacokinetics of quinapril and enalapril in a prospective genotype panel study in healthy volunteers. Methods In a fixed‐order crossover study, 10 healthy volunteers with the CES1 c.428G/A genotype and 12 with the c.428G/G genotype ingested a single 10 mg dose of quinapril and enalapril with a washout period of at least 1 week. Plasma concentrations of quinapril and quinaprilat were measured for up to 24 h and those of enalapril and enalaprilat for up to 48 h. Their excretion into the urine was measured from 0 h to 12 h. Results The area under the plasma concentration–time curve from 0 h to infinity (AUC 0–∞ ) of active enalaprilat was 20% lower in subjects with the CES1 c.428G/A genotype than in those with the c.428G/G genotype (95% confidence interval of geometric mean ratio 0.64, 1.00; P = 0.049). The amount of enalaprilat excreted into the urine was 35% smaller in subjects with the CES1 c.428G/A genotype than in those with the c.428G/G genotype ( P = 0.044). The CES1 genotype had no significant effect on the enalaprilat to enalapril AUC 0–∞ ratio or on any other pharmacokinetic or pharmacodynamic parameters of enalapril or enalaprilat. The CES1 genotype had no significant effect on the pharmacokinetic or pharmacodynamic parameters of quinapril. Conclusions The CES1 c.428G > A SNV decreased enalaprilat concentrations, probably by reducing the hydrolysis of enalapril, but had no observable effect on the pharmacokinetics of quinapril.